Asset Details
Do you wish to reserve the book?
Food-Grade Organisms as Vaccine Biofactories and Oral Delivery Vehicles
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Food-Grade Organisms as Vaccine Biofactories and Oral Delivery Vehicles
Do you wish to request the book?
Food-Grade Organisms as Vaccine Biofactories and Oral Delivery Vehicles
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Food-Grade Organisms as Vaccine Biofactories and Oral Delivery Vehicles
2016
Overview
The use of food-grade organisms as recombinant vaccine expression hosts and delivery vehicles has been explored during the past 25 years, opening new avenues for vaccinology. Considering that oral immunization is a beneficial approach in terms of costs, patient comfort, and protection of mucosal tissues, the use of food-grade organisms can lead to highly advantageous vaccines in terms of costs, easy administration, and safety. The organisms currently used for this purpose are bacteria (Lactobacillus and Bacillus), yeasts, algae, plants, and insect species. Herein, a comparative and updated scenario on the production of oral vaccines in food-grade organisms is provided and placed in perspective. The status of clinical evaluations and the adoption of this technology by the industry are highlighted.
Recombinant food-grade organisms are being used for vaccine production and delivery as food-grade vaccines (FGVs).
The concept of FGVs is highly advantageous in terms of costs, administration, and safety.
FGVs are currently produced in some bacteria, yeast, algae, plants, and insect species.
FGVs with improved immunogenicity are being successfully explored for painless mucosal administration.
Several FGVs are under clinical evaluation, and the current adoption of this technology by the industry indicates a potential to benefit global healthcare systems.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Algae
/ Animals
/ bacteria
/ Cholera
/ Food
/ hosts
/ Humans
/ industry
/ insects
/ patients
/ plant
/ silkworm
/ tissues
/ Vaccines
/ Vaccines, Edible - administration & dosage
/ Vaccines, Edible - isolation & purification
/ Vaccines, Synthetic - administration & dosage
/ Vaccines, Synthetic - isolation & purification
/ yeast
/ Yeasts
